MitrAssist Medical Ltd.
“Valve-in-valve” approach to mitral regurgitation
This article was originally published in Start Up
Just as people improve their vision by wearing glasses or contact lenses instead of repairing or replacing their eyes, a mitral valve prosthesis from Israeli-based MitrAssist Medical Ltd. neither repairs nor replaces damaged mitral valves in the heart, but rather it augments and enhances native valve function. The company’s implant is placed on top of the native valve and anchored securely. This “valve-in-valve” approach is designed to prevent leakage and restore normal blood flow.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.